Human moricizine metabolism. I. Isolation and identification of metabolites in human urine

Xenobiotica

Volumn 27, Issue 2, 1997, Pages 217-229

  Richards, L E ^a   Pieniaszek Jr , H J ^a   Shatzmiller, S ^b,d   Page, G O ^a   Blom, K F ^a   Read, J M ^a,c   Davidson, A F ^a   Confalone, P N ^a  

^a DUPONT COMPANY   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c Laboratory Management Systems   (United States)

^d IMI TAMI Institute for Research and Development Ltd   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; DRUG METABOLITE; MORACIZINE; PHENOTHIAZINE DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG URINE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORAL DRUG ADMINISTRATION;

ADULT; ANTI-ARRHYTHMIA AGENTS; FEMALE; HUMANS; MALE; MOLECULAR STRUCTURE; MORICIZINE; PRODRUGS;

CANIS FAMILIARIS;

EID: 0031034409     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982597240703     Document Type: Article

References (25)

1. ARAVAGIRI, M., HAWES, E. M. and MIDHA, K. K., 1984, Radioimmunoassay for the sulfoxide metabolite of Trifluoroperazine and its application to a kinetic study in humans. Journal of Pharmaceutical Science, 73, 1383-1387.
2. BECKETT, A. H., BEAVEN, M. A. and ROBINSON, A. E., 1963, Metabolism of chlorpromazine in humans. Biochemical Pharmacology, 12, 779-794.
3. BELOBORODOV, V. L., RODIONOV, A. P., TYUKAVKINA, N. A., KLIMOV, A. V., KAVERINA, N. V., KOLESNIK, Y. A., GRITSENKO, A. N. and LESINA, V. P., 1989, Ethacizin metabolism in humans. Xenobiotica, 19, 755-767.
4. FITTON, A. and BUCKLEY, M. M.-T., 1990, Moricizine: a review of its pharmacological properties and therapeutic efficacy in cardiac arrhythmias. Drugs, 40, 138-167.
5. GRITSENKO, A. N., ERMAKOVA, Z. I. and ZHURAVLEV, S. V., 1972, The synthesis of ethmozine: A new preparation with antiarrhythmic action. Khimiko-Farmatsevticheskii Zhurnal, 6, 17-19.
6. HONDEGHEM, L. M. and KATZUNG, B. G., 1977, Time- and voltage-dependent interactions of antiarrhythmic drugs with sodium channels. Biochimica et Biophysica Acta, 472, 373-398.
7. KAVERNA, N. V., LYSKOVTSEV, V. V., SENOVA, Z. P. and GRIGORYEVA, E. K., 1984, Ethacizin: pharmacological properties and prospects of clinical employment. Kardiologiya, 24, 52-57 (in Russian). Cumulated Index Medicus 25, book 4.
8. KAVERNA, N. V., LYSKOVTSEV, V. V., SENOVA, Z. P. and GRIGORYEVA, E. K., 1984, Ethacizin: pharmacological properties and prospects of clinical employment. Kardiologiya, 24, 52-57 (in Russian). Cumulated Index Medicus 25, book 4.
9. KOLLER, B. and FRANZ, M. R., 1994, New classification of moricizine and propafenone based on electrophysiologic and electrocardiographic data from isolated rabbit heart. Journal of Cardiovascular Pharmacology, 24, 753-760.
10. MAKIELSKI, J. C., 1990, State dependence of Ethacizin and Ethmozin block of sodium current in voltage clamped and internally perfused cardiac Purkinje cells. Journal of Pharmacology and Experimental Therapeutics, 253, 1110-1117.
11. a Prediction for Organic Acids and Bases (London: Chapman & Hall), pp. 27-31.
12. PIENIASZEK, H. J. JR, DAVIDSON, A. F., MCENTEGART, C. M., QUON, C. Y., SAMPLINER, R. E. and MAYERSOHN, M., 1994, The effect of hepatic disease on the disposition of moricizine in humans. Biopharmaceutics and Drug Disposition, 15, 243-252.
13. SCHUBERT, B., HERING, S., BODEWEI, R., ROSENSHTRAUKH, L. V. and WOLLENBERGER, A. J., 1986, Use and voltage-dependent depression by Ethmozine (moricizine) of the rapid inward sodium current in single rat ventricular muscle cells. Journal of Cardiovascular Pharmacology, 8, 358-366.
14. SHEEHAN, E. W., 1990, Rat and human urinary metabolites of Ethmozine. PhD thesis, University of Pittsburgh.
15. SHEEHAN, E. W., WONG, L., ZEMAITIS, M. A., BUCHNER, J. and LO, H. H., 1985, Studies of Ethmozine metabolism by LC/MS/MS. In Proceedings of the 33rd Annual Conference on Mass Spectroscopy and Allied Topics, San Diego, CA, 26-31 May, (Sante Fe, New Mexico: American Society for Mass Spectroscopy and Applied Topics) 782-783 (abs).
16. SHELDON, R. S., HILL, R. J., TAOVIS, M. and WILSON, L. M., 1991, Aminoalkyl structural requirements for interaction of lidocaine with the class 1 antiarrhythmic receptor on rat cardiac myocytes. Molecular Pharmacology, 39, 609-614.
17. SINGH, B. N. and VAUGHAN WILLIAMS, E. M., 1970, The effect of Amiodarone, a new anti-anginal drug on cardiac muscle. British Journal of Pharmacology, 39, 657-667.
18. SNYDER, D. W., 1989, Class 1B antiarrhythmic drugs: tocainide, mexilitine, and moricizme. Journal of the Louisiana State Medical Society, 141, 21-25.
19. VAUGHAN WILLIAMS, E. M., 1992, The relevance of cellular to clinical electrophysiology classifying antiarrhythmic actions. Journal of Cardiovascular Pharmacology, 20 (suppl. 2), S1-7.
20. VIKHLYAEV, Y. I., ZHERDEV, V. P., GRITSENKO, A. N. and ERMAKOVA, Z. I., 1977, Features of Ethmozin metabolism [English translation]. Farmakologiya i Toksikologiya, 40, 19-22.
21. WALDO, A. L., ROGERS, W. J., PRATT, C. M. and CAPONE, R. J., 1988, Effects of encainide, flecainide, imipramme, and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS. American Journal of Cardiology, 61, 501-509.
22. WEISEL, C. A., TAYLOR, R. B., MOSHER, H. S. and WHITMORE, F. C., 1945, Substituted β-aminopropionic esters. Journal of the American Chemical Society, 67, 1071-1072.
23. WHITMORE, F. C., MOSHER, H. S., ADAMS, R. R., TAYLOR, R. B., CAPIN, E. C., WEISEL, C. and YANKO, W., 1944, Basically substituted aliphatic nitriles and their catalytic reduction to amines. Journal of the American Chemical Society, 66, 725-731.
24. 14C]N-ethoxycarbonyl-3-morpholinosydnonimine (molsidomine) in man. Xenobiotica, 17, 93-104.
25. YANG, J. M. and CHAN, K., 1995, Isolation and characterization of sulphoxidation metabolites of moricizine in rat and human biological fluids. Methods and Findings in Experimental and Clinical Pharmacology, 17, 415-421.